JNJ

228.27

-0.51%↓

UNH

369.83

+0.22%↑

TMO

470.55

-1.31%↓

ISRG

459.32

+0.8%↑

ABT

90.03

-0.54%↓

JNJ

228.27

-0.51%↓

UNH

369.83

+0.22%↑

TMO

470.55

-1.31%↓

ISRG

459.32

+0.8%↑

ABT

90.03

-0.54%↓

JNJ

228.27

-0.51%↓

UNH

369.83

+0.22%↑

TMO

470.55

-1.31%↓

ISRG

459.32

+0.8%↑

ABT

90.03

-0.54%↓

JNJ

228.27

-0.51%↓

UNH

369.83

+0.22%↑

TMO

470.55

-1.31%↓

ISRG

459.32

+0.8%↑

ABT

90.03

-0.54%↓

JNJ

228.27

-0.51%↓

UNH

369.83

+0.22%↑

TMO

470.55

-1.31%↓

ISRG

459.32

+0.8%↑

ABT

90.03

-0.54%↓

Search

Certara Inc

Fermé

SecteurSoins de santé

6.17 0.82

Résumé

Variation du prix de l'action

24h

Actuel

Min

6.12

Max

6.3

Chiffres clés

By Trading Economics

Revenu

-7.4M

-5.9M

Ventes

-968K

104M

P/E

Moyenne du Secteur

100.714

67.147

Marge bénéficiaire

-5.688

Employés

1,515

EBITDA

8.6M

32M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+44.07% upside

Dividendes

By Dow Jones

Prochains Résultats

11 mai 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-77M

957M

Ouverture précédente

5.35

Clôture précédente

6.17

Sentiment de l'Actualité

By Acuity

50%

50%

186 / 347 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

Certara Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

30 avr. 2026, 23:08 UTC

Résultats

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 avr. 2026, 23:07 UTC

Résultats

Australia's Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 avr. 2026, 22:20 UTC

Résultats

Australia's ANZ Raises 1st Half Profit 9%, Warns of Coming Iran Impacts

30 avr. 2026, 23:48 UTC

Market Talk

Nikkei May Rise After Gains on Wall Street -- Market Talk

30 avr. 2026, 23:47 UTC

Market Talk

Global Equities Roundup: Market Talk

30 avr. 2026, 23:47 UTC

Market Talk

Coles's Earnings Views Likely to Edge Down Despite Positives -- Market Talk

30 avr. 2026, 23:27 UTC

Market Talk

Liontown Lithium Recovery Expected to Improve -- Market Talk

30 avr. 2026, 23:22 UTC

Résultats

Apple's Incoming CEO John Ternus Makes Appearance as Company Bests Expectations -- Update

30 avr. 2026, 23:20 UTC

Market Talk

Wildcat Resources Stands Out Among Lithium Developers -- Market Talk

30 avr. 2026, 22:52 UTC

Résultats

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 avr. 2026, 22:33 UTC

Résultats

Zhejiang Expressway: Impairment Loss Weighed on Net >0576.HK

30 avr. 2026, 22:32 UTC

Résultats

Zhejiang Expressway 1Q Net CNY1.31B Vs. Net CNY1.48B >0576.HK

30 avr. 2026, 22:32 UTC

Résultats

Zhejiang Expressway 1Q Rev CNY5.32B Vs. CNY4.36B >0576.HK

30 avr. 2026, 22:24 UTC

Acquisitions, Fusions, Rachats

Mineral Resources: Also Reflects Time Needed to Implement Corporate Restructure For JV

30 avr. 2026, 22:23 UTC

Acquisitions, Fusions, Rachats

Mineral Resources: Revised Timetable Reflects Time Needed to Get Regulatory Approvals

30 avr. 2026, 22:23 UTC

Acquisitions, Fusions, Rachats

Mineral Resources: Now Expects Deal to Complete in 1H FY2027

30 avr. 2026, 22:23 UTC

Acquisitions, Fusions, Rachats

Mineral Resources: Executes Key Formal Agreements With Posco on Stake Sale

30 avr. 2026, 22:11 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

30 avr. 2026, 22:11 UTC

Market Talk

Global Equities Roundup: Market Talk

30 avr. 2026, 22:11 UTC

Market Talk

Apple Says Demand for Lower-Cost Laptop is Off the Charts -- Market Talk

30 avr. 2026, 22:05 UTC

Résultats

Australia's ANZ Raises 1H Profit 9%, Warns of Coming Iran Impacts

30 avr. 2026, 21:57 UTC

Résultats

ANZ CEO: Increase in Collective Provisions Reflects Risk>ANZ.AU

30 avr. 2026, 21:56 UTC

Résultats

ANZ CEO: Minimal Impact on ANZ's Credit, Capital, Liquidity>ANZ.AU

30 avr. 2026, 21:56 UTC

Résultats

ANZ CEO: No Material Increase in New Cases of Household Hardship>ANZ.AU

30 avr. 2026, 21:55 UTC

Résultats

ANZ CEO: Households Entered Crisis With Generally Strong Balance Sheets>ANZ.AU

30 avr. 2026, 21:54 UTC

Résultats

ANZ CEO: No Material Change in Overall Corporate Borrowing Behavior >ANZ.AU

30 avr. 2026, 21:54 UTC

Résultats

ANZ CEO: Corporate Customers Have Been Building Capital, Liquidity Against Shocks>ANZ.AU

30 avr. 2026, 21:53 UTC

Résultats

ANZ CEO: Much of Iran Conflict's Potential Impact Remains Ahead>ANZ.AU

30 avr. 2026, 21:49 UTC

Résultats

ANZ Group 1H Total Operating Income A$11.20B Vs. A$10.995B>ANZ.AU

30 avr. 2026, 21:49 UTC

Résultats

ANZ Group 1H Customer Deposits A$770.7B Vs. A$756.6B>ANZ.AU

Comparaison

Variation de prix

Certara Inc prévision

Objectif de Prix

By TipRanks

44.07% hausse

Prévisions sur 12 Mois

Moyen 8.5 USD  44.07%

Haut 10 USD

Bas 7 USD

Basé sur 8 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

8 ratings

3

Achat

5

Maintien

0

Vente

Score Technique

By Trading Central

11.27 / 12.79Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Very Strong Bullish Evidence

Long Terme

Strong Bullish Evidence

Sentiment

By Acuity

186 / 347Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Moyen

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Certara Inc

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
help-icon Live chat